Printer Friendly

CYTRX CORPORATION ANNOUNCES APPOINTMENT OF VICE PRESIDENT, HUMAN RESOURCES

 NORCROSS, Ga., March 26 /PRNewswire/ -- CytRx Corporation (NASDAQ-NMS: CYTR) announced today the appointment of William B. Fleck as its vice president, Human Resources.
 With this appointment, Fleck will assume responsibility for coordinating all of the company's human resource policies and programs including compensation, benefits, recruiting, employee relations, training and strategic planning.
 Fleck was previously with Central Health Services, Inc., of Atlanta, where he served as director of Human Resources and Training. He received his masters degree in personnel administration from Florida State University and also holds a bachelor's degree in pre-law. Prior to Central Health, Fleck served in senior resource positions with MCI Communications and Harris/3M.
 Jack J. Luchese, president and chief executive officer, said: "Will is an important addition to the CytRx management team. His talents and experience are essential for the orderly growth of our company and the timely implementation of business strategy as we continue to build CytRx into a fully integrated critical care pharmaceutical company."
 CytRx Corporation is engaged in the research and development of critical care pharmaceutical products for the treatment of vascular and infectious diseases, burns, and cancer. Vetlife(TM), a CytRx subsidiary, is developing feed additives to enhance growth in food animals. Vaxcel(TM), a second subsidiary, is developing an advanced vaccine adjuvant system for human and veterinary use.
 -0- 3/26/93
 /CONTACT: CytRx Corporation public relations, 404-368-9500/
 (CYTR)


CO: CytRx Corporation ST: Georgia IN: MTC SU: PER

BR-BN -- AT004 -- 9981 03/26/93 09:52 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 26, 1993
Words:246
Previous Article:ALBANY HERALD SWITCHES TO MORNING EDITION
Next Article:RJR NABISCO NAMES RICCIARDI, VON DER HEYDEN TO NEW OFFICE OF THE CHAIRMAN
Topics:


Related Articles
CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION FOR SICKLE CELL
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF VICE PRESIDENT, MEDICAL & REGUALTORY AFFAIRS
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF PRESIDENT AND CEO OF VAXCEL, INC.
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF PRESIDENT AND CEO OF VAXCEL, INC.
CYTRX CORPORATION ANNOUNCES PURCHASE OF FACILITIES
CYTRX CORPORATION RETAINS OPPENHEIMER & CO., INC.
CYTRX NAMES FRANCIS J. CASIERI TO HEAD EXPANDING OPERATIONS
VAXCEL ANNOUNCES NEW VICE PRESIDENT OF RESEARCH AND DEVELOPMENT
CytRx Licenses TranzFect Poloxamer Technology to Vical.
CytRx to Present at the 3rd International Metabolic Diseases Drug Discovery World Summit.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters